Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy
Duchenne muscular dystrophy (DMD) is the most clinically significant neuromuscular disease affecting GI motility, with smooth-muscle dysfunction causing gastroparesis, intestinal dysmotility, and constipation that can critically impact postoperative outcomes and require aggressive management. 1
Primary Neuromuscular Diseases with GI Involvement
The neuromuscular diseases most commonly impairing gastrointestinal motility include:
Duchenne Muscular Dystrophy (DMD)
- DMD causes GI smooth-muscle dysfunction throughout the digestive tract 1
- Manifests as gastroparesis, intestinal dysmotility, and constipation
- GI dysfunction can impair breathing postoperatively when abdominal distention hampers diaphragmatic excursion 1
- Gut dysmotility increases gastric distention risk during non-invasive ventilation 1
Management requires proactive intervention:
- Initiate bowel regimens preoperatively and postoperatively to prevent constipation 1
- Consider prokinetic GI medications 1
- Use gastric decompression with nasogastric tube in patients with GI dysmotility 1
- Start enteral feeding via small-diameter tube or parenteral nutrition if oral feeding delayed 24-48 hours postoperatively 1
Myotonic Dystrophy (MD)
- GI involvement occurs frequently at any level of the digestive tract 2
- Upper tract: dysphagia, heartburn, regurgitation, dyspepsia 2
- Lower tract: abdominal pain, bloating, altered bowel habits 2
- Digestive symptoms may be the first sign of dystrophic disease, preceding musculoskeletal features 2
- Patients may adapt gradually with little symptom awareness, requiring targeted diagnostic techniques (manometry, electrogastrography, scintigraphy) 2
- Positive correlation exists between disease duration and GI severity, but not with skeletal muscle involvement degree 2
MNGIE (Mitochondrial Neurogastrointestinal Encephalomyopathy)
- 100% prevalence of GIT involvement 3
- Exhibits distinctive small bowel dysmotility pattern: repetitive bursts of spasmodic contractions without normal fasting/postprandial patterns 4
- Severe cachexia and progressive dysmotility invariably lead to death 4
- Critical pitfall: objective motor dysfunction detected even without severe digestive symptoms 4
- Early investigation indicated since symptoms don't predict objective findings 4
Other Neuromuscular Diseases with GI Involvement
Among neuropathies, ALS and Guillain-Barré syndrome most commonly affect GI motility 3. Mitochondrial disorders (MELAS, Leigh syndrome, Pearson syndrome) and myasthenia also feature GI involvement 3.
Clinical Approach
The key clinical pitfall is underestimating GI involvement when symptoms are mild or absent. In MNGIE, severe motor dysfunction exists without proportionate symptoms 4. In myotonic dystrophy, gradual impairment leads to patient adaptation and symptom underreporting 2.
Treatment remains primarily symptomatic with prokinetic agents, anti-dyspeptic drugs, and laxatives targeting motility disorders 2. However, in DMD specifically, aggressive perioperative management with bowel regimens, prokinetic medications, gastric decompression, and early nutritional support is essential to prevent respiratory compromise and optimize outcomes 1.